{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:46:01Z","timestamp":1787168761046,"version":"build-2736575974"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>CMV infection remains the most common clinically significant infection in pediatric allogeneic hematopoietic stem cell (HCT) recipients, with seropositive recipients of transplants from seronegative donors at the highest risk for complications. In recent years, letermovir, a novel antiviral with a favorable toxicity profile, was approved first for adults and more recently for pediatric patients for the primary prophylaxis of CMV infection and disease in high-risk HCT recipients. Growing evidence from real-life data regarding the safety and efficacy of letermovir has transformed the landscape of CMV disease in HCT transplant recipients and led to a paradigm shift from a preemptive approach to prophylaxis. Other novel additions to the diagnosis, risk stratification, and treatment of CMV include the measurement of CMV-specific cellular-mediated immunity and the approval of maribavir as a treatment option for resistant\/refractory CMV infection and disease. Other prevention and treatment modalities currently under development include virus-specific T cells, monoclonal antibodies, and vaccines. Despite these promising advancements, additional pediatric-specific studies are needed to better understand the viral and immunological implications of these novel preventive and therapeutic methods in this patient population.<\/jats:p>","DOI":"10.3389\/fped.2025.1663600","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:38:34Z","timestamp":1757655514000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Revisiting cytomegalovirus in pediatric allogeneic hematopoietic stem cell transplant recipients: current strategies for prevention and management in the letermovir era"],"prefix":"10.3389","volume":"13","author":[{"given":"Lisa","family":"Hiskey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego R.","family":"Hijano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramia","family":"Zakhour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for transplantation and cellular therapy series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100131","DOI":"10.1016\/j.ejcped.2023.100131","article-title":"Virus infections after allogeneic stem cell transplantation in children","volume":"2","author":"Rauwolf","year":"2023","journal-title":"Rev EJC Paediatr Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14740\/jh1376","article-title":"Prevalence of viral infections and serious complications in pediatric hematopoietic stem cell transplant patients: a ten-year single-institution retrospective study","volume":"14","author":"Lau","year":"2025","journal-title":"J Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41409-023-01944-2","article-title":"CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality","volume":"58","author":"Eberhardt","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.cmi.2021.10.008","article-title":"The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"28","author":"Chuleerarux","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.bbmt.2017.07.025","article-title":"Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring","volume":"23","author":"Yong","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/QCO.0000000000000502","article-title":"Invasive fungal disease and cytomegalovirus infection: is there an association?","volume":"31","author":"Yong","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"110302","DOI":"10.1016\/j.clim.2024.110302","article-title":"Cytomegalovirus infection is associated with thymic dysfunction and chronic graft-versus-host disease after pediatric hematopoietic stem cell transplantation","volume":"265","author":"Kielsen","year":"2024","journal-title":"Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e13627","DOI":"10.1111\/tid.13627","article-title":"Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: a multicenter study from the Spanish hematopoietic transplantation and cell therapy group","volume":"23","author":"Bueno","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"103.e1","DOI":"10.1016\/j.jtct.2023.09.025","article-title":"Risk factors associated with survival following ganciclovir prophylaxis through day +100 in cytomegalovirus at-risk pediatric allogeneic stem cell transplantation recipients: development of cytomegalovirus viremia associated with significantly decreased 1-year survival","volume":"30","author":"Klejmont","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1080\/17512433.2018.1500897","article-title":"Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients","volume":"11","author":"Foolad","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B12","first-page":"344","article-title":"American Academy of pediatrics committee on infectious diseases, cytomegalovirus infection","volume-title":"Red Book: 2024\u20132027 Report of the Committee on Infectious Diseases","author":"Kimberlin","year":"2024"},{"key":"B13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13643-022-02004-4","article-title":"Prevalence, incidence, and risk factors associated with cytomegalovirus infection in healthcare and childcare worker: a systematic review and meta-analysis","volume":"11","author":"Balegamire","year":"2022","journal-title":"Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3389\/fcimb.2020.00130","article-title":"Cytomegalovirus latency and reactivation: an intricate interplay with the host immune response","volume":"10","author":"Forte","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988\u20132004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-guidelines of the American society of transplantation infectious diseases community of practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1394006","DOI":"10.3389\/fped.2024.1394006","article-title":"Case report: approaches for managing resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplantation recipients","volume":"12","author":"Song","year":"2024","journal-title":"Front Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1039938","DOI":"10.3389\/fped.2022.1039938","article-title":"Prevention and management of human cytomegalovirus in pediatric HSCT recipients: a review","volume":"10","author":"Hiskey","year":"2022","journal-title":"Front Pediatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.bbmt.2020.07.002","article-title":"Letermovir prophylaxis decreases burden of cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant","volume":"26","author":"Johnsrud","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/INF.0000000000004208","article-title":"Pharmacokinetics, safety, and efficacy of letermovir for cytomegalovirus prophylaxis in adolescent hematopoietic cell transplantation recipients","volume":"43","author":"Groll","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e70006","DOI":"10.1111\/tid.70006","article-title":"Efficacy and safety of letermovir for cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation recipients: a systematic review, meta-analysis, and meta-regression","volume":"27","author":"Aldalati","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1016\/S1473-3099(25)00069-6","article-title":"Recommendations from the 10th European conference on infections in leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies","volume":"25","author":"Ljungman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/infdis\/jiad386","article-title":"Cytomegalovirus viral load threshold to guide preemptive therapy in hematopoietic cell transplant recipients: correlation with cytomegalovirus disease","volume":"229","author":"Sadowska-Klasa","year":"2024","journal-title":"J Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e14358","DOI":"10.1111\/tid.14358","article-title":"Cytomegalovirus viral load at initiation of pre-emptive antiviral therapy impacts cytomegalovirus dynamics in pediatric allogeneic hematopoietic cell transplantation recipients","volume":"26","author":"Gutierrez","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1093\/jpids\/piae005","article-title":"Cytomegalovirus cell-mediated immunity assays in pediatric transplantation","volume":"13","author":"Otto","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0246191","DOI":"10.1371\/journal.pone.0246191","article-title":"Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients","volume":"16","author":"Seo","year":"2021","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e13220","DOI":"10.1111\/petr.13220","article-title":"Quantiferon-Cytomegalovirus assay: a potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients","volume":"22","author":"Paouri","year":"2018","journal-title":"Pediatr Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"211.e1","DOI":"10.1016\/j.jtct.2022.01.008","article-title":"Human cytomegalovirus-specific T-cell reconstitution and late-onset cytomegalovirus infection in hematopoietic stem cell transplantation recipients following letermovir prophylaxis","volume":"28","author":"Gabanti","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B37","doi-asserted-by":"publisher","first-page":"S276","DOI":"10.1016\/j.bbmt.2018.12.341","article-title":"Breakthrough CMV infections on letermovir prophylaxis in CMV-seropositive allogeneic hematopoietic cell transplant (allo-HCT) recipients","volume":"25","author":"Shigle","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/iid3.431","article-title":"Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients","volume":"9","author":"Royston","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"ofad169","DOI":"10.1093\/ofid\/ofad169","article-title":"CMV Infection after letermovir primary prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients","volume":"10","author":"Chavaz","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41409-024-02209-2","article-title":"Letermovir for cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the infectious diseases working group of Italian association of pediatric hematology-oncology (AIEOP)","volume":"59","author":"Galaverna","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1182\/bloodadvances.2024012849","article-title":"Immune milestones to predict CMV after letermovir","volume":"8","author":"Little","year":"2024","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","first-page":"106220","DOI":"10.1016\/j.jinf.2024.106220","article-title":"Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: a multi-centre observational study","volume":"89","author":"Hopff","year":"2024","journal-title":"J Infect"},{"key":"B43","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12185-022-03348-2","article-title":"Risk factors for late cytomegalovirus infection after completing letermovir prophylaxis","volume":"116","author":"Mori","year":"2022","journal-title":"Int J Hematol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"El Chaer","year":"2016","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/cid\/ciab298","article-title":"Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era","volume":"73","author":"Sassine","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B46","article-title":"LIVTENCITY (maribavir) label","year":"2021"},{"key":"B47","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1093\/jpids\/piad059","article-title":"Current and emerging antiviral agents in the prevention and treatment of cytomegalovirus in pediatric transplant recipients","volume":"13","author":"Valencia Deray","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e14444","DOI":"10.1111\/tid.14444","article-title":"Real-World experience with maribavir for treatment of refractory or resistant cytomegalovirus infection in hematopoietic cell transplant recipients and hematologic malignancy patients","volume":"27","author":"Daher","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/v16121889","article-title":"Real-World comparison of maribavir to foscarnet for the treatment of cytomegalovirus in solid organ and hematopoietic stem cell transplant recipients","volume":"16","author":"Ogawa","year":"2024","journal-title":"Viruses"},{"key":"B52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/jpids\/piae093.071","article-title":"Maribavir use in pediatric immunocompromised hosts: a case series to talk about real-world experience","volume":"13","author":"Doshi","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1097\/MPH.0000000000002841","article-title":"Use of maribavir for multidrug resistant cytomegaloviremia in a pediatric oncology patient","volume":"46","author":"Fisher","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jtct.2023.01.027","article-title":"Third-Party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplantation in children and young adults","volume":"29","author":"Galletta","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1093\/jpids\/piad077","article-title":"Virus-Specific T cells for the treatment of systemic infections following allogeneic hematopoietic cell and solid organ transplantation","volume":"13","author":"Green","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"B56","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1182\/bloodadvances.2022007103","article-title":"Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant","volume":"6","author":"Jiang","year":"2022","journal-title":"Blood Adv"},{"key":"B57","doi-asserted-by":"publisher","first-page":"306","DOI":"10.7326\/M19-2511","article-title":"Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial","volume":"172","author":"Aldoss","year":"2020","journal-title":"Ann Intern Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/ajh.26824","article-title":"Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus-specific T cells in the recipient: a novel strategy to limit antiviral prophylaxis","volume":"98","author":"La Rosa","year":"2023","journal-title":"Am J Hematol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/TP.0000000000005260","article-title":"Phase 2, randomized, double-blind, placebo-controlled study of fiztasovimab (NPC-21) for kidney transplant recipients at high risk of cytomegalovirus infection (LionHeart21)","volume":"109","author":"Ichimaru","year":"2025","journal-title":"Transplantation"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0285672","DOI":"10.1371\/journal.pone.0285672","article-title":"A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B","volume":"18","author":"Okamoto","year":"2023","journal-title":"PLoS One"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1663600\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:38:35Z","timestamp":1757655515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1663600\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":60,"alternative-id":["10.3389\/fped.2025.1663600"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1663600","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"1663600"}}